Selective Norepinephrine Reuptake Inhibitors (NRIs)
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Using this site does not create a doctor-patient relationship.
Drug information changes as the FDA updates labeling, and we cannot guarantee it is complete or current. Verify critical details with your pharmacist or physician.
Emergencies: If you think you may have a medical emergency, call 911 immediately. For a suspected overdose, call Poison Control at 1-800-222-1222. Report side effects to the FDA MedWatch program at fda.gov/medwatch or 1-800-FDA-1088.
See our Terms of Use and Editorial Policy.
Overview
A class of medications that selectively inhibit the reuptake of norepinephrine in the brain, increasing norepinephrine availability at synapses. Unlike stimulant ADHD medications, NRIs are not classified as controlled substances and have no significant abuse potential.
How do selective norepinephrine reuptake inhibitors (nris) work?
Selectively block the norepinephrine transporter (NET), increasing norepinephrine availability in the prefrontal cortex and other brain regions involved in attention and executive function.
Drugs in this class
- Atomoxetine (Strattera)